Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib combined with gemcitabine and docetaxel for recurrent or metastatic primary bone malignancies
ChiCTR2200058759Phase 2Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Sun Yat-sen University
- Start
- Apr 2022
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib, gemcitabine and docetaxel in Primary bone malignancy (None.), osteosarcoma (OS) and Malignant Fibrous Histiocytoma of Bone (MFH), sponsored by The First Affiliated Hospital of Sun Yat-sen University. Primary endpoint: Progression-free survival. Planned start Apr 2022; status: not yet recruiting.
02
Drugs
anlotinibgemcitabinedocetaxel
03
Conditions
Primary bone malignancy (None.)osteosarcoma (OS)Malignant Fibrous Histiocytoma of Bone (MFH)
Beyond the preview
Go deeper on ChiCTR2200058759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200058759.